

### **Amendment to the Claims**

The following listing of claims will replace all prior versions and listings of claims.

#### **Listing of Claims:**

1. (Previously Presented) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
- 2-10. (Canceled)

11. (Previously Presented) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (g) a variant of SEQ ID NO:Y;
  - (h) an allelic variant of SEQ ID NO:Y; or
  - (i) a species homologue of the SEQ ID NO:Y.
12. (Previously Presented) The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. (Previously Presented) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
- 14-16. (Canceled)
17. (Previously Presented) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

18. (Previously Presented) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
  - (a) determining the presence or absence of a mutation in the polynucleotide of claim 1;
  - and
  - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. (Previously Presented) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
  - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
  - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20. (Previously Presented) A method for identifying a binding partner to the polypeptide of claim 11 comprising:
  - (a) contacting the polypeptide of claim 11 with a binding partner; and
  - (b) determining whether the binding partner effects an activity of the polypeptide.
21. (Canceled)
22. (Canceled)
23. (Previously Presented) The product produced by the method of claim 20.
24. (Canceled)
25. (New) An isolated protein comprising amino acid residues 20 to 290 of SEQ ID NO:65.
26. (New) The isolated protein of claim 25 which comprises amino acid residues 1 to 290 of SEQ ID NO:65.
27. (New) The isolated protein of claim 25 which comprises amino acid residues 2 to 290 of SEQ ID NO:65.

28. (New) The isolated protein of claim 25 wherein the amino acid residues are fused to a heterologous polypeptide.
29. (New) The isolated protein of claim 28 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
30. (New) The protein of claim 25 wherein said protein is glycosylated.
31. (New) The protein of claim 25 wherein said protein is fused to polyethylene glycol.
32. (New) A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.
33. (New) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 25; and
  - (b) recovering the protein of claim 25 from the host cell culture.
34. (New) An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 20 to 290 of SEQ ID NO:65.
35. (New) The isolated protein of claim 34 wherein said polypeptide sequence is at least 95% identical to amino acid residues 20 to 290 of SEQ ID NO:65.
36. (New) The isolated protein of claim 34 wherein the polypeptide sequence is fused to a heterologous polypeptide.
37. (New) The isolated protein of claim 36 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
38. (New) The protein of claim 34 wherein said protein is glycosylated.
39. (New) The protein of claim 34 wherein said protein is fused to polyethylene glycol.

40. (New) A composition comprising the protein of claim 34 and a pharmaceutically acceptable carrier.
41. (New) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 34; and
  - (b) recovering the protein of claim 34 from the host cell culture.
42. (New) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acids 20 to 290 of SEQ ID NO:65.
43. (New) The isolated protein of claim 42 which consists of at least 50 contiguous amino acid residues of amino acids 20 to 290 of SEQ ID NO:65.
44. (New) The isolated protein of claim 42 wherein the amino acid residues are fused to a heterologous polypeptide.
45. (New) The isolated protein of claim 44 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
46. (New) The protein of claim 42 wherein said protein is glycosylated.
47. (New) The protein of claim 42 wherein said protein is fused to polyethylene glycol.
48. (New) A composition comprising the protein of claim 42 and a pharmaceutically acceptable carrier.
49. (New) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 42; and
  - (b) recovering the protein of claim 42 from the host cell culture.
50. (New) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.

51. (New) The isolated protein of claim 50 which comprises the amino acid sequence of the full-length polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
52. (New) The isolated protein of claim 50 which comprises the amino acid sequence of the full-length polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648, excepting the N-terminal methionine.
53. (New) The isolated protein of claim 50 wherein the amino acid sequence is fused to a heterologous polypeptide.
54. (New) The isolated protein of claim 53 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
55. (New) The protein of claim 50 wherein said protein is glycosylated.
56. (New) The protein of claim 50 wherein said protein is fused to polyethylene glycol.
57. (New) A composition comprising the protein of claim 50 and a pharmaceutically acceptable carrier.
58. (New) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 50; and
  - (b) recovering the protein of claim 50 from the host cell culture.
59. (New) An isolated protein comprising a polypeptide sequence which is at least 90% identical to the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
60. (New) The isolated protein of claim 59 wherein said polypeptide sequence is at least 95% identical to the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.

61. (New) The isolated protein of claim 59 wherein the polypeptide sequence is fused to a heterologous polypeptide.
62. (New) The isolated protein of claim 61 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
63. (New) The protein of claim 59 wherein said protein is glycosylated.
64. (New) The protein of claim 59 wherein said protein is fused to polyethylene glycol.
65. (New) A composition comprising the protein of claim 59 and a pharmaceutically acceptable carrier.
66. (New) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 59; and
  - (b) recovering the protein of claim 59 from the host cell culture.
67. (New) An isolated protein consisting of at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
68. (New) The isolated protein of claim 67 which consists of at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
69. (New) The isolated protein of claim 67 wherein the amino acid residues are fused to a heterologous polypeptide.
70. (New) The isolated protein of claim 69 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
71. (New) The protein of claim 67 wherein said protein is glycosylated.

72. (New) The protein of claim 67 wherein said protein is fused to polyethylene glycol.
73. (New) A composition comprising the protein of claim 67 and a pharmaceutically acceptable carrier.
74. (New) An isolated protein produced by a method comprising:
- (a) culturing a host cell under conditions suitable to produce the protein of claim 67; and
  - (b) recovering the protein of claim 67 from the host cell culture.